224 related articles for article (PubMed ID: 17330403)
1. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
3. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
6. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
7. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
Sugiyama H
Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
[TBL] [Abstract][Full Text] [Related]
8. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
9. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccines for myeloid leukaemias.
Dao T; Scheinberg DA
Best Pract Res Clin Haematol; 2008 Sep; 21(3):391-404. PubMed ID: 18790445
[TBL] [Abstract][Full Text] [Related]
11. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
12. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
13. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Nakajima H; Elisseeva OA; Harada Y; Li Z; Tatsumi N; Kamino E; Shirakata T; Nishida S; Taniguchi Y; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Dec; 52(12):591-600. PubMed ID: 19120973
[TBL] [Abstract][Full Text] [Related]
14. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice.
Eslami NS; Shokrgozar MA; Mousavi A; Azadmanesh K; Nomani A; Apostolopoulos V; Day S; Amanzadeh A; Alimohammadian MH
Mol Immunol; 2012 Jul; 51(3-4):325-31. PubMed ID: 22525006
[TBL] [Abstract][Full Text] [Related]
16. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
17. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.
Doubrovina ES; Doubrovin MM; Lee S; Shieh JH; Heller G; Pamer E; O'Reilly RJ
Clin Cancer Res; 2004 Nov; 10(21):7207-19. PubMed ID: 15534094
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
[TBL] [Abstract][Full Text] [Related]
19. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
20. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
Ohta H; Hashii Y; Yoneda A; Takizawa S; Kusuki S; Tokimasa S; Fukuzawa M; Tsuboi A; Murao A; Oka Y; Oji Y; Aozasa K; Nakatsuka S; Sugiyama H; Ozono K
Pediatr Hematol Oncol; 2009 Jan; 26(1):74-83. PubMed ID: 19206012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]